Across TCGA pan-cancer cohorts, TMCO2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMCO2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMCO2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMCO2 expression acts as an unfavorable survival marker.

LUAD and CESC are the cancer types where TMCO2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.280	0.813	<.001	39	view →
CESC	OS	Median	All	0.117	0.588	.046	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TMCO2 tumor-vs-normal RNA expression · all TMCO2 data types